Research progress in small molecule drugs based on high-density lipoprotein for anti-atherosclerosis
10.16438/j.0513-4870.2017-0979
- VernacularTitle:基于高密度脂蛋白的抗动脉粥样硬化小分子药物研究现状
- Author:
Bei-bei MA
1
;
Cong BIAN
1
;
Bin HONG
1
;
Yu DU
1
;
Xiao-fang CHEN
1
Author Information
1. Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
- Publication Type:REVIEWS
- Keywords:
high-density lipoprotein;
atherosclerosis;
reverse cholesterol transport;
apolipoprotein A-I;
ATP-binding cassette transporter A1;
liver X receptor;
cholesteryl ester transfer protein inhibitor
- From:
Acta Pharmaceutica Sinica
2018;53(3):328-335
- CountryChina
- Language:Chinese
-
Abstract:
A large number of epidemiological data have shown that the high-density lipoprotein cholesterol level is negatively related to atherosclerotic cardiovascular disease, suggesting that high-density lipoprotein may have the effect of anti-atherosclerosis. It may play the role of anti-atherosclerosis, through the promotion of cholesterol reverse transport, anti-inflammatory, antioxidant, and against thrombosis and fibrinolysis and so on. Among them, reverse cholesterol transport which is mainly regulated by apolipoprotein A-I, ATP-binding cassette transporter 1, liver X receptor and cholesteryl ester transfer protein, may play a major role in the maintenance of cholesterol homeostasis and reversing the course of atherosclerosis. These regulatory factors may be potential targets in high density lipoprotein-based drug discovery. In this review, these key proteins are discussed for the current status of small molecule drugs against atherosclerosis.
